<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148990</url>
  </required_header>
  <id_info>
    <org_study_id>ASCLIN 002/2017</org_study_id>
    <nct_id>NCT03148990</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella</brief_title>
  <acronym>BIOMR</acronym>
  <official_title>A Phase II / III, Clinical Trial to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella, Produced by Bio-Manguinhos / Fiocruz in 11-month-old Infants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oswaldo Cruz Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Measles and rubella are highly contagious acute viral diseases. As per WHO, several evidences&#xD;
      demonstrate the benefit for providing the universal access to vaccines containing measles and&#xD;
      rubella antigens, mainly due to, respectively, mortality in children and malformations in&#xD;
      fetuses. This is a Phase I-III, Controlled, randomized and double blind for the evaluation&#xD;
      double viral vaccine anti-measles and rubella (MR), which is developed and produced at&#xD;
      Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in&#xD;
      human beings. 432 eligible volunteers (11-month-old infants), will be vaccinated and&#xD;
      monitored for local and systemic adverse events and titration of antibodies. The study will&#xD;
      last 11 months in total.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II-III, controlled, randomized and double blind for the evaluation of a&#xD;
      double viral vaccine anti measles and rubella (MR), which is under the development at&#xD;
      Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for use in&#xD;
      human beings. 432 eligible volunteers (11-month-old infants), will be vaccinated and&#xD;
      monitored for local and systemic adverse events and immunogenicity. The study will last 11&#xD;
      months in total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Actual">August 12, 2020</completion_date>
  <primary_completion_date type="Actual">August 12, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two intervention groups (MR vaccine and MMR vaccine), with 1 dose of vaccine in each group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity analysis of the study vaccine</measure>
    <time_frame>42 days after the 1st dose of MR or MMR</time_frame>
    <description>To evaluate imune response between post and pre-vaccination antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reatogenicity analysis of the study vaccine</measure>
    <time_frame>30 days after the 1st dose of MR or MMR</time_frame>
    <description>To assess the occurrence of serious adverse events among individuals who received MR and MMR vaccines.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">432</enrollment>
  <condition>Rubella</condition>
  <condition>Measles</condition>
  <arm_group>
    <arm_group_label>Measles and Rubella vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Measles, Mumps and Rubella vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles and Rubella vaccine</intervention_name>
    <description>Administration of the experimental vaccine (MR).</description>
    <arm_group_label>Measles and Rubella vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, Mumps and Rubella vaccine</intervention_name>
    <description>Administration of the comparator vaccine (MMR).</description>
    <arm_group_label>Measles, Mumps and Rubella vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both sex;&#xD;
&#xD;
          -  Good health (no significant medical history);&#xD;
&#xD;
          -  11 months of age on the first dose of vaccine;&#xD;
&#xD;
          -  To be up-to-date with the national vaccination calendar;&#xD;
&#xD;
          -  Availability for follow-up throughout the study period;&#xD;
&#xD;
          -  Willing to provide name, address, telephone and other contact information in order to&#xD;
             be contacted, whenever needed (example: in case of missing any scheduled visit,&#xD;
             contact for confirmation of scheduling a visit, urgent safety notifications);&#xD;
&#xD;
          -  Willing to strictly follow the study protocol;&#xD;
&#xD;
          -  At least one legal guardian of the research participants must be able to understand&#xD;
             and sign the informed consent form;&#xD;
&#xD;
          -  Legal guardians by the research participants who can understand the child's inability&#xD;
             to participate in another clinical trial during the time they are participating in the&#xD;
             study;&#xD;
&#xD;
          -  Legal guardian with intellectual capacity to fill out the signs of signs and symptoms&#xD;
             at home.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous vaccination against measles and rubella;&#xD;
&#xD;
          -  Personal history of measles or rubella;&#xD;
&#xD;
          -  Personal history of anaphylactic shock, asthma, urticaria or other hypersensitivity&#xD;
             reaction to previous vaccinations, or who are allergic or hypersensitive to vaccine&#xD;
             components of the study;&#xD;
&#xD;
          -  Use of antiallergic injections with antigens within 14 days or less prior to&#xD;
             vaccination;&#xD;
&#xD;
          -  Use of immunoglobulin in the last 12 months prior to vaccination;&#xD;
&#xD;
          -  Use of blood products in the last 12 months prior to vaccination;&#xD;
&#xD;
          -  Use of any type of vaccine less than 30 days prior to study vaccination;&#xD;
&#xD;
          -  Use of injectable vaccines less than 42 days after study vaccination;&#xD;
&#xD;
          -  Chronic use of any medications (except homeopathic medicines and trivial medication&#xD;
             such as saline and vitamins);&#xD;
&#xD;
          -  Previous use of immunosuppressive or cytotoxic medication;&#xD;
&#xD;
          -  Use of systemic therapy with high doses of steroids;&#xD;
&#xD;
          -  Use of any type of medication in a clinical trial within 12 months prior to&#xD;
             vaccination;&#xD;
&#xD;
          -  Personal history of clinically significant neurological, cardiovascular, respiratory,&#xD;
             hepatic, renal, haematological, rheumatologic or autoimmune diseases;&#xD;
&#xD;
          -  Personal history of coagulopathies diagnosed by a physician or report of capillary&#xD;
             fragility;&#xD;
&#xD;
          -  Personal history of seizures;&#xD;
&#xD;
          -  Personal history of an active (eg any cancer) or treated malignant disease that may&#xD;
             recur during the study;&#xD;
&#xD;
          -  Personal history of sickle cell anemia;&#xD;
&#xD;
          -  Asplenia (absence of spleen or removal of the spleen);&#xD;
&#xD;
          -  HIV positive or history of any immunosuppressive disease;&#xD;
&#xD;
          -  Presence of any disorder which, in the opinion of the principal investigator, may&#xD;
             interfere with the evaluation of the study objectives;&#xD;
&#xD;
          -  Legal guardian with limited capacity for adherence to the study, according to the&#xD;
             researcher's evaluation;&#xD;
&#xD;
          -  Impossibility of blood collection for pre-vaccine evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kleber G Luz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Estudos e Pesquisas em Moléstias Infecciosas Ltda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas em Moléstias Infecciosas Ltda (CPCLIN)</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59.025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Secretaria Municipal de Saúde do Estado do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double Viral Vaccine Measles and Rubella</keyword>
  <keyword>Safety Efficacy Imunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

